Syneos Health Signs Agreement with Optimal Clinical Trials Ltd Site in New Zealand

July 31, 2023

MORRISVILLE, N.C. – July 31, 2023 – Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced that it has signed an agreement with Optimal Clinical Trials Ltd. The agreement will expand the Company’s clinical trial capabilities across a broad range of therapeutic areas in New Zealand, including Oncology, CNS and Vaccines.
Optimal Clinical Trials Ltd now joins the Syneos Health Catalyst Site Program, introduced in 2016 to strengthen collaborations with clinical research sites worldwide. The Catalyst Site Program harnesses insights from sites across the globe to drive continuous improvement and develop best practices in clinical research delivery. Together, Syneos Health and Optimal Clinical Trials Ltd will enable sites, sponsors and patients to collaborate in multiple therapeutic areas, fueling engagement through transparent communication channels during the entire clinical trial process.
“Our agreement with Optimal Clinical Trials Ltd is part of Syneos Health’s global strategy to accelerate our clinical development impact in this rapidly growing and changing market,” said Dr. Ken J. Lee, General Manager and Regional Head, Clinical Development, APAC, Syneos Health. “This collaboration supports our strong focus on customers, achieving consistent delivery and quality for their programs, and executing customized solutions that address their unique and complex needs.”

Dr Liz Smaill, General Manager at Optimal Clinical Trials Ltd welcomed the signature of the agreement: “Thank you for having Optimal Clinical Trials as a Catalyst site. We are looking forward to collaborating with Syneos Health as part of this program.”

Syneos Health has relationships with more than 100 Catalyst sites worldwide and the Company has been acknowledged by the Society for Clinical Research Sites as a recipient of the Eagle Award for demonstrating dedication to establishing strong site partnerships.


About Syneos Health
Syneos Health® (Nasdaq:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. 

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics.

Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment. 
To learn more about how we are Shortening the distance from lab to life®, visit or subscribe to our podcast.

Syneos Investor Relations Contact:               
Ronnie Speight                                                    
Senior Vice President, Investor Relations           
+1 919 745 2745                                                  
[email protected]                                                            

Syneos Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
+1 908 763 3428
[email protected]